Board of Directors
Stephen R. Biggar, M.D., Ph.D. has been the Chairman of our Board of Directors since June 2016 and has been a director since 2013. Dr. Biggar is a partner at Baker Bros. Advisors LP, a fund management company focused on long-term investments in life-sciences companies. From April 2002 to October 2006, he served as a principal with Baker Bros. Advisors LP, which he had joined as an associate in April 2000. Dr. Biggar serves on the boards of Kiniksa Pharmaceuticals, Ltd., and Vivelix Pharmaceuticals, Ltd. Dr. Biggar also served as a director for Synageva BioPharma Corp. Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester.
Julian C. Baker has served as a director of Acadia since December 2015. Mr. Baker is a Managing Partner at Baker Bros. Advisors LP, which manages long-term investment funds, focused on publicly traded life sciences companies, for major university endowments and foundations. Mr. Baker and his brother Felix Baker, Ph.D., founded the firm in 2000. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch family. Mr. Baker currently serves on the board of directors of Genomic Health, Inc. and Incyte Corporation. Mr. Baker holds an A.B. Magna Cum Laude from Harvard University.
Laura A. Brege has served as a director of Acadia since May 2008. Ms. Brege is Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. Prior to joining Cervantes Life Science Partners, Ms. Brege served as Chief Executive Officer and President of Nodality, Inc., a privately held biotechnology company focused in oncology and immunology from September 2012 to July 2015. Previously, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc. from June 2006 to December 2011, including Executive Vice President and Chief Operating Officer. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies. Prior to Red Rock, she was Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege serves on the boards of Dynavax Technologies Corporation, HLS Therapeutics Inc., Pacira BioSciences, Inc., and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
Jim Daly has served as a director of Acadia since January 2016. Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. During his tenure, he was instrumental in re-accelerating the launch of Jakafi® and driving sustained growth. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for ten years, holding multiple leadership positions. In his last role, Mr. Daly served as Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen’s Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline (GSK) where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair®. He currently serves on the board of directors of argenx SE, Chimerix Inc., Bellicum Pharmaceuticals, Inc. and Halozyme Therapeutics. Mr. Daly earned his B.S. in Pharmacy and M.B.A. from the University at Buffalo, The State University of New York.
Stephen R. Davis has served as our Chief Executive Officer and a member of our board of directors since 2015. Mr. Davis joined Acadia in July 2014 as Executive Vice President, Chief Financial Officer and Chief Business Officer. He was appointed Interim Chief Executive Officer in March 2015 and named President and Chief Executive Officer in September 2015. Mr. Davis brings over 25 years of executive-level experience in the pharmaceutical industry and more than 25 years of experience on the boards of directors of publicly held biopharmaceutical companies. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc., and in numerous executive roles at Neurogen Corporation, including Chief Executive Officer. Mr. Davis currently serves on the Board of Directors of Bellicum Pharmaceuticals, Inc. and Heron Therapeutics. He also recently served on the boards of directors of Synageva BioPharma Corp. and Furiex Pharmaceuticals, Inc. Early in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.
Elizabeth Garofalo, M.D., has served as a director of Acadia since September 2020. Since 2016, Dr. Garofalo has served as the Principal for EAG Pharma Consulting LLC. Prior to that, Dr. Garofalo served in numerous leadership roles including as Senior Vice President and Global Head of Clinical Development and member of the Novartis Global Development Leadership Team, Chair of the Novartis Portfolio Stewardship Board and Co-Head of the Novartis Neuroscience Franchise. Prior to that she was Vice President and Head of the Neuroscience Therapy Area at Astellas. She started her career at Parke-Davis/Pfizer where she had jobs of increasing responsibility including Ann Arbor Site Head of Neuroscience and Ann Arbor Site Head of Worldwide Regulatory Affairs. Dr. Garofalo currently serves on the board for the Institute for Advanced Clinical Trials in Children and is the Chair of the Business Advisory Board for the Epilepsy Foundation of America. She earned her M.D. from the Indiana University School of Medicine where she completed her Pediatric Residency. She completed fellowships in Pediatric Neurology and Epilepsy at the University of Michigan Medical School.
Edmund P. Harrigan, M.D. has served as a director of Acadia since November 2015. Dr. Harrigan served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a 3,500-person team in 80 countries that was responsible for collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Dr. Harrigan’s previous executive leadership roles at Pfizer include serving as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain. Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years. He currently serves on the boards of Incyte Corporation, Karuna Therapeutics, Inc. and PhaseBio Pharmaceuticals, Inc. Dr. Harrigan earned his B.A. degree in Chemistry from St. Anselm College, his M.D. from the University of Massachusetts at Worcester, and trained in neurology at Boston University.
Daniel B. Soland has served as a director of Acadia since March 2015. Mr. Soland served as Chief Executive Officer of uniQure N.V., a human gene therapy company, from December 2015 through September 2016. He previously served as Senior Vice President and Chief Operating Officer of ViroPharma starting in 2008 until it was acquired in 2014, and as Vice President and Chief Commercial Officer of the Company from 2006 to 2008. During his tenure at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Mr. Soland served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility from 1993 to 2002, including as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the board of directors of DBV Technologies SA. Mr. Soland earned his B.S. in Pharmacy from the University of Iowa.